Edition:
India

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

5.85USD
14 Nov 2019
Change (% chg)

-- (--)
Prev Close
$5.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
326,115
52-wk High
$6.31
52-wk Low
$3.43

Latest Key Developments (Source: Significant Developments)

Progenics Pharma Says On Nov. 11, Mark Baker Resigned As CEO
Tuesday, 12 Nov 2019 

Nov 12 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS - ON NOVEMBER 11, MARK BAKER TO RESIGN AS CEO OF CO EFFECTIVE IMMEDIATELY- SEC FILING.PROGENICS PHARMACEUTICALS INC - FOLLOWING BAKER'S RESIGNATION, PATRICK FABBIO, CO'S CFO WILL PERFORM FUNCTIONS OF PRINCIPAL EXECUTIVE OFFICER.  Full Article

Progenics Pharmaceuticals Says Q3 Revenue Of $5.6 Million Versus $5.3 Million
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 3 CONDOR TRIAL OF PYL EXPECTED BY YEAR END.PROGENICS PHARMACEUTICALS INC - Q3 REVENUE OF $5.6 MILLION VERSUS $5.3 MILLION.PROGENICS PHARMACEUTICALS INC - ENDED Q3 WITH CASH AND CASH EQUIVALENTS OF $64.5 MILLION.PROGENICS PHARMACEUTICALS INC - CONTINUING PLANS TO EXPAND MANUFACTURING CAPACITY FOR IODINE-BASED PRODUCTS AND TO PROVIDE REDUNDANCY.PROGENICS PHARMACEUTICALS -EXPECTS ADDITIONAL IODINE MANUFACTURING CAPABILITY TO BECOME AVAILABLE FROM CONTRACT MANUFACTURING PARTNERS FROM Q2 2020.PROGENICS PHARMACEUTICALS INC - GUIDANCE FOR 2019 AZEDRA SALES IS APPROXIMATELY $2.0 MILLION.PROGENICS PHARMACEUTICALS INC - INTEND TO COMMENCE LIFE CYCLE MANAGEMENT TRIAL NEXT YEAR.PROGENICS PHARMACEUTICALS INC - CURRENTLY ESTIMATE THAT NDA FOR PYL WILL BE SUBMITTED TO FDA IN JULY 2020.PROGENICS PHARMACEUTICALS INC - WILL NOT HOLD Q3 2019 EARNINGS CONFERENCE CALL DUE TO PENDING TRANSACTION WITH LANTHEUS.  Full Article

Progenics Pharmaceuticals Q3 Earnings Per Share Estimate $-0.24 -- Refinitiv Ibes Data
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Progenics Pharmaceuticals Inc ::Q3 LOSS PER SHARE $0.22.Q3 EARNINGS PER SHARE ESTIMATE $-0.24 -- REFINITIV IBES DATA.  Full Article

Progenics Pharmaceuticals Says Unanimously Elected Karen Ferrante, And Nicole Williams As Co-Chairs Of Board
Saturday, 19 Oct 2019 

Oct 18 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS INC - UNANIMOUSLY ELECTED KAREN FERRANTE, AND NICOLE WILLIAMS AS CO-CHAIRS OF BOARD, EFFECTIVE AS OF OCTOBER 17, 2019.  Full Article

Lantheus To Acquire Progenics In All-Stock Transaction
Wednesday, 2 Oct 2019 

Oct 2 (Reuters) - Lantheus Holdings Inc ::LANTHEUS TO ACQUIRE PROGENICS TO FORM A LEADING PRECISION DIAGNOSTICS IMAGING AND THERAPEUTICS COMPANY.LANTHEUS HOLDINGS - PROGENICS SHAREHOLDERS TO RECEIVE 0.2502 SHARES OF LANTHEUS COMMON STOCK FOR EACH SHARE OF PROGENICS STOCK IN ALL-STOCK DEAL.LANTHEUS HOLDINGS INC - PROGENICS SHAREHOLDERS WILL RECEIVE 0.2502 SHARES OF LANTHEUS HOLDINGS STOCK FOR EACH SHARE OF PROGENICS STOCK.LANTHEUS HOLDINGS INC - EXCHANGE RATIO REPRESENTS 35% AGGREGATE OWNERSHIP STAKE IN COMBINED COMPANY.LANTHEUS HOLDINGS INC - DEAL INTENDED TO BE TAX-FREE TO PROGENICS' STOCKHOLDERS FOR U.S. FEDERAL INCOME TAX PURPOSES.LANTHEUS HOLDINGS INC - COMBINED COMPANY WILL BE LED BY LANTHEUS CHIEF EXECUTIVE OFFICER MARY ANNE HEINO.LANTHEUS HOLDINGS INC - COMBINED COMPANY WILL TRADE ON NASDAQ UNDER TICKER SYMBOL: LNTH.LANTHEUS HOLDINGS INC - EXPECTS TO GENERATE APPROXIMATELY $15 TO $20 MILLION IN RUN-RATE COST SAVINGS BY 2022 FROM DEAL.LANTHEUS HOLDINGS - TRANSACTION EXPECTED TO ENHANCE CO'S CASH FLOW GENERATION & BE ACCRETIVE TO ADJUSTED & REPORTED EPS BY 2022 AND 2023, RESPECTIVELY.  Full Article

Velan Capital Launches Consent Solicitation To Reconstitute Progenics Pharma Board
Wednesday, 18 Sep 2019 

Sept 18 (Reuters) - Velan Capital::VELAN LAUNCHES CONSENT SOLICITATION TO RECONSTITUTE THE PROGENICS BOARD WITH ITS FIVE HIGHLY-QUALIFIED, INDEPENDENT DIRECTOR NOMINEES.VELAN CAPITAL - CONTINUE TO BELIEVE THERE IS SIGNIFICANT VALUE TO BE REALIZED AT PROGENICS .VELAN CAPITAL SAYS BELIEVES REMOVAL OF THREE LONGEST-TENURED DIRECTORS AT PROGENICS PHARMACEUTICALS IS NECESSARY.VELAN CAPITAL - WILL ISSUE "COMPREHENSIVE STRATEGIC AND OPERATIONAL PLAN" TO HELP PROGENICS PHARMACEUTICALS "REACH ITS FULL POTENTIAL" IN COMING WEEKS.VELAN CAPITAL - A KEY ELEMENT OF OUR "STRATEGIC & OPERATIONAL" PLAN WILL BE PROGENICS' BOARD IDENTIFYING A CEO TO LEAD PROGENICS GOING FORWARD.VELAN CAPITAL LP - VELAN DIRECTLY BENEFICIALLY OWNS 8 MILLION SHARES OF COMMON STOCK OF PROGENICS PHARMACEUTICALS.  Full Article

Progenics Pharmaceuticals Q2 Loss Per Share $0.23
Friday, 9 Aug 2019 

Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.Q2 LOSS PER SHARE $0.23.Q2 EARNINGS PER SHARE ESTIMATE $-0.19 -- REFINITIV IBES DATA.ENDED Q2 WITH CASH AND CASH EQUIVALENTS OF $84.8 MILLION.PROGENICS PHARMACEUTICALS - ENROLLMENT COMPLETED AHEAD OF SCHEDULE IN PHASE 3 CONDOR TRIAL OF PYL(TM )((18)F-DCFPYL); TOPLINE DATA EXPECTED BY YEAR END 2019.  Full Article

Velan Capital Sends Letter To Progenics Pharmaceuticals' Board
Thursday, 20 Jun 2019 

June 20 (Reuters) - Velan Capital:VELAN CAPITAL- URGE PROGENICS' STOCKHOLDERS TO VOTE AGAINST RE-ELECTION OF CROWLEY & KISHBAUCH ON GREEN PROXY CARD .VELAN CALLS ON PROGENICS PHARMACEUTICALS' BOARD TO BACK UP RECENT CLAIMS.VELAN CAPITAL - ISSUED STATEMENT RESPONDING TO LATEST LETTER FROM PROGENICS' BOARD OF DIRECTORS.VELAN CAPITAL SAYS UPCOMING ANNUAL MEETING SHOULD BE SOLELY ABOUT PERFORMANCE OF PROGENICS PHARMACEUTICALS' BOARD.VELAN CAPITAL SAYS URGE PROGENICS PHARMACEUTICALS' STOCKHOLDERS TO VOTE AGAINST RE-ELECTION OF MESSRS. CROWLEY & KISHBAUCH ON GREEN PROXY CARD.  Full Article

Progenics Pharma Reports Q1 Loss Per Share $0.22
Thursday, 9 May 2019 

May 9 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.Q1 LOSS PER SHARE $0.22.Q1 EARNINGS PER SHARE ESTIMATE $-0.19 -- REFINITIV IBES DATA.ENDED Q1 WITH CASH AND CASH EQUIVALENTS OF $109.6 MILLION.QTRLY REVENUE TOTALED $4.3 MILLION, UP FROM $3.2 MILLION IN Q1 OF 2018.Q1 REVENUE VIEW $4.2 MILLION -- REFINITIV IBES DATA.  Full Article

Altiva Management Believes Progenics’ Operational, Clinical, Commercial And Financial Performance Can Be Significantly Improved
Friday, 5 Apr 2019 

April 5 (Reuters) - Progenics Pharmaceuticals Inc ::ALTIVA MANAGEMENT INC SAYS BELIEVE THAT PROGENICS’ OPERATIONAL, CLINICAL, COMMERCIAL AND FINANCIAL PERFORMANCE CAN BE SIGNIFICANTLY IMPROVED.ALTIVA MANAGEMENT REPORTS STAKE OF 6 PERCENT IN PROGENICS PHARMACEUTICALS AS OF MARCH 27, 2019 - SEC FILING.ALTIVA MANAGEMENT - ON MARCH 15, VELAN DELIVERED TO PROGENICS LETTER NOMINATING 6 DIRECTOR CANDIDATES.ALTIVA MANAGEMENT SAYS BELIEVE THAT PROGENICS' SHARES, WHEN PURCHASED, REPRESENTED "ATTRACTIVE INVESTMENT OPPORTUNITY".ALTIVA MANAGEMENT - VENKATARAMAN & SARPANGAL HAVE AIMED TO ENGAGE IN DIALOGUE WITH PROGENICS' MANAGEMENT TEAM.  Full Article